420 likes | 1.55k Views
Acute Leukemia. David Lee, MD, FRCPC. Overview. Concepts, biology Epidemiology Clinical and laboratory manifestations Diagnosis Management and prognosis. Classification of leukemias. Acute. Chronic. Myeloid origin. Acute Myeloid Leukemia (AML). Chronic Myeloid Leukemia (CML).
E N D
Acute Leukemia David Lee, MD, FRCPC
Overview • Concepts, biology • Epidemiology • Clinical and laboratory manifestations • Diagnosis • Management and prognosis
Classification of leukemias Acute Chronic Myeloid origin Acute Myeloid Leukemia (AML) Chronic Myeloid Leukemia (CML) Lymphoid origin Acute Lymphoblastic Leukemia (ALL) Chronic Lymphocytic Leukemia (CLL)
ALL naïve germinal center B-lymphocytes Plasma cells Lymphoid progenitor T-lymphocytes Neutrophils AML Myeloid progenitor Eosinophils Hematopoietic stem cell Basophils Monocytes Platelets Red cells
myeloblast promyelocyte myelocyte metamyelocyte band neutrophil Myeloid maturation MATURATION Adapted and modified from U Va website
Acute Leukemia • accumulation of blasts in the marrow
How to distinguish AML vs CMLfrom looking at peripheral blood Myeloid cell CML AML normal blasts qq promyelocytes q myelocytes q metamyelocytes q bands q neutrophils q # q
Significance of adult acute leukemia • a hematologic urgency • usually fatal within weeks to months without chemotherapy • with treatment, high mortality due to disease or treatment-related complications (unlike childhood acute leukemia) • notify Hematologist promptly if acute leukemia is suspected
ALL mainly children M > F curable in 70% of children curable in minority of adults AML mainly adults M > F curable in minority of adults Classification of acute leukemias
Two-hit model of leukemogenesis Loss of function of transcription factors needed for differentiation eg. AML1-ETO CBFb-SMMHC PML-RARa Gain of function mutations of tyrosine kinases eg. FLT3, c-KIT mutations N- and K-RAS mutations BCR-ABL TEL-PDGFbR differentiation block enhanced proliferation Acute Leukemia +
Causes of acute leukemias • idiopathic (most) • underlying hematologic disorders • chemicals, drugs • ionizing radiation • viruses (HTLV I) • hereditary/genetic conditions
Clincal manifestations • symptoms due to: • marrow failure • tissue infiltration • leukostasis • constitutional symptoms • other (DIC) • usually short duration of symptoms
Marrow failure • neutropenia: infections, sepsis • anemia: fatigue, pallor • thrombocytopenia: bleeding
Infiltration of tissues/organs • enlargement of liver, spleen, lymph nodes • gum hypertrophy • bone pain • other organs: CNS, skin, testis, any organ
A B C Chloromas NEJM 1998
Leukostasis • accumulation of blasts in microcirculation with impaired perfusion • lungs: hypoxemia, pulmonary infiltrates • CNS: stroke • only seen with WBC >> 50 x 109/L
Constitutional symptoms • fever and sweats common • weight loss less common
Laboratory features • WBC usually elevated, but can be normal or low • blasts in peripheral blood • normocytic anemia • thrombocytopenia • neutropenia • DIC
Bone marrow in acute leukemia • necessary for diagnosis • useful for determining type • useful for prognosis • Acute leukemias are defined by the presence of > 20% blasts in bone marrow (% of nucleated marrow cells)
Distinguishing AML from ALL • light microscopy • AML: Auer rods, cytoplasmic granules • ALL: no Auer rods or granules. • flow cytometry • special stains (cytochemistry)
Treatment of acute leukemias Choice of Rx is influenced by: • type (AML vs ALL) • age • curative vs palliative intent
Principles of treatment • combination chemotherapy • first goal is complete remission • further Rx to prevent relapse • supportive medical care • transfusions, antibiotics, nutrition • psychosocial support • patient and family
Chemotherapy for acute leukemias • Phases of ALL treatment • induction • intensification • CNS prophylaxis • maintenance • Phases of AML treatment • induction • consolidation (post-remission therapy) post-remission therapy
Hematopoietic stem cell transplantation • permits “rescue” from otherwise excessively toxic treatment • additional advantage of graft-vs-leukemia effect in allogeneic transplants • trade-off for allogeneic transplantation: greater anti-leukemic effect but more toxic
Prognosis Adult AML Adult ALL similar to or worse than AML
Overview • Concepts, biology • Epidemiology • Clinical and laboratory manifestations • Diagnosis • Management and prognosis